ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

NCT00135304 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

170

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG: Sensipar®
DRUG: Vitamin D

Sponsor

Amgen